Michael Lim

TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.

TL;DR: The first clinical data indicating that HIF-1alpha may play an important role in human cancer progression are provided, indicating adaptations to a hypoxic microenvironment that are correlated with tumor invasion, metastasis, and lethality.

TL;DR: The combination of PD-1 blockade and localized radiation therapy results in long-term survival in mice with orthotopic brain tumors, providing strong preclinical evidence to support combination trials in patients with GBM.

TL;DR: The current standard of care for patients with glioblastoma includes surgery, temozolomide chemotherapy, radiotherapy, and corticosteroids, all of which have immunosuppressive effects; the implications for combining the current standard-of-care treatment modalities with immunotherapies, potential biomarkers of response, and future directions for gliOBlastoma immuno-oncology are examined.

TL;DR: Nivolumab monotherapy did not improve overall survival compared with bevacizumab in the treatment of recurrent glioblastoma, and additional research is needed to find out why.